Allogeneic CAR T Cell Therapy for Cancer

Autologous chimeric antigen receptor (CAR) T cell therapy, produced from the patient's own T cells, has changed the treatment landscape for hematologic malignancies but has some drawbacks that prevent large-scale clinical application, including logistical complexities in supply, patient T cell...

Full description

Saved in:
Bibliographic Details
Published inAnnual review of cancer biology Vol. 8; no. 1; pp. 227 - 243
Main Authors Sasu, Barbra Johnson, Lauron, Elvin James, Schulz, Thomas, Cheng, Hsin-Yuan, Sommer, Cesar
Format Journal Article
LanguageEnglish
Published 12.06.2024
Online AccessGet full text

Cover

More Information
Summary:Autologous chimeric antigen receptor (CAR) T cell therapy, produced from the patient's own T cells, has changed the treatment landscape for hematologic malignancies but has some drawbacks that prevent large-scale clinical application, including logistical complexities in supply, patient T cell health, treatment delays, and limited manufacturing slots. Allogeneic, or off-the-shelf, CAR T cell therapies have the potential to overcome many of the limitations of autologous therapies, with the aim of bringing benefit to all patients eligible for treatment. This review highlights the progress and challenges of allogeneic cell therapies for cancer and the various approaches that are being evaluated preclinically and in clinical trials to enhance the persistence and antitumor efficacy of allogeneic CAR T cells, including new strategies to avoid immune rejection.
ISSN:2472-3428
2472-3428
DOI:10.1146/annurev-cancerbio-062822-023316